game of the year 2024
This image released by Paramount Pictures shows Matthew McConaughey in a scene from the film “Interstellar.” (Paramount Pictures via AP) This image released by Paramount Pictures shows promotional art for the film “Interstellar.” (Paramount Pictures via AP) This cover image released by St. Martin’s Press shows “Miss May Does Not Exist: The Life and Work of Elaine May, Hollywood’s Hidden Genius” by Carrie Courogen. (St. Martin’s Press via AP) This cover image released by A24 shows “How Directors Dress: On Set, In the Edit, and Down the Red Carpet,” a book about what directors wear, featuring over 200 archival photos of filmmakers in action. (A24 Films via AP) This cover image shows the first issue of “The Metrograph,” a biannual print publication for film fans by the movie theater. (The Metrograph via AP) This image released by the Academy Museum of Motion Pictures shows the cover image of the catalogue for their “Color in Motion: Chromatic Exploration of Cinema” exhibit. (Academy Museum of Motion Pictures via AP) This image released by the Academy Museum of Motion Pictures shows “Matrix” sweatshirt for sale in conjunction with its Cyberpunk exhibition, designed by Brain Dead Studios. (Academy Museum of Motion Pictures via AP) This image released by Paramount Pictures shows Matthew McConaughey in a scene from the film “Interstellar.” (Paramount Pictures via AP) By LINDSEY BAHR Do you have a someone in your life who plays Vulture’s Cinematrix game every morning? Or maybe they have the kitchen television turned to Turner Classic Movies all day and make a point of organizing Oscar polls at work? Hate to break it to you: They might be a hard-to-please cinephile. But while you might not want to get into a winless debate over the “Juror No. 2” release or the merits of “Megalopolis” with said person, they don’t have to be hard to buy gifts for. The Associated Press has gathered up some of the best items out there to keep any movie lover stylish and informed. While Christopher Nolan dreams up his next film, fans can tide themselves over by revisiting his modern classic “Interstellar,” which will be back in IMAX theaters on the weekend of Dec. 6, followed by the home release of a new collector’s edition on 4K Ultra HD and Blu-ray ($59.95). A third disc in the set, available Dec. 10, contains more than two hours of bonus content, like a never-before-seen storyboard sequence, and new interviews with Nolan, producer Emma Thomas and famous fans Peter Jackson and Denis Villeneuve . Elaine May does not give interviews anymore. But thankfully that didn’t deter writer Carrie Courogen, who did a remarkable job stitching together the life of one of our culture’s most fascinating, and prickly, talents. “Miss May Does Not Exist” is full of delightful anecdotes about the sharp and satirical comedian who gained fame as one half of Nichols and May and went on to direct films like “The Heartbreak Kid” and “Mikey and Nicky.” Courogen writes about May’s successes, flops and her legendary scuffles with the Hollywood establishment. It’s a vital companion to Mark Harris’ biography of Mike Nichols . Macmillan. $30. The Academy Museum of Motion Pictures has an exclusive new “Matrix” sweatshirt for sale in conjunction with its Cyberpunk exhibition. Brain Dead Studios designed and created several items, including the black hoodie ($140), a white rabbit tee ($54) and a pint glass ($18). If you can’t make it to Los Angeles to check out the “Color in Motion” exhibit for yourself, the Academy Museum also has a beautiful new companion book for sale ($55) charting the development of color technology in film and its impact. It includes photos from films like “The Red Shoes,” “Vertigo,” “2001: A Space Odyssey,” and images of rare prints from the silent era. The Academy Museum Store is having a sale (20% off everything) from Nov. 28 to Dec. 2. Related Articles Things To Do | US airports with worst weather delays during holiday season Things To Do | The right book can inspire the young readers in your life, from picture books to YA novels Things To Do | These holiday gifts change the game when building fires, printing photos, watching birds and more Things To Do | ‘Gladiator II’ review: Are you not moderately entertained? Things To Do | Beer pairings for your holiday feasts Want to look like a real film festival warrior, the kind who sees five movies a day, files a review and still manages to make the late-night karaoke party? You’re going to need the ultimate status tote from the independent streaming service MUBI . Simple, to-the-point and only for people in the know. $25. Film magazines may be an endangered species, but print is not dead at The Metrograph . Manhattan’s coolest movie theater is starting a biannual print publication “for cinephiles and cultural connoisseurs alike.” The first issue’s cover art is by cinematographer Ed Lachman (“Carol”), and contributors include the likes of Daniel Clowes, Ari Aster, Steve Martin and Simon Rex. There’s also a conversation with Clint Eastwood. It’s currently available for pre-order and will be in bookstores Dec. 10 for $25 ($15 for Metrograph members). This is not a book about filmmaking styles, camera angles and leadership choices. It’s literally about what directors wear. “How Directors Dress: On Set, in the Edit, and Down the Red Carpet” ($40) has over 200 archival photos of filmmakers in action: Spike Lee in his basketball caps, Sofia Coppola in her Charvet button-ups, Steven Spielberg’s denim on denim and many more. With a forward by the always elegant Joanna Hogg and writing from some of the top fashion journalists, it’s a beautiful look at how filmmakers really dress for work — and might even be a source of inspiration.Prime Minister leads tributes to former US president Jimmy Carter
Digging themselves out: With parade cancelled, Londoners make best of snowy situation
Percentages: FG .420, FT .732. 3-Point Goals: 6-21, .286 (Jennings 2-3, Avery 2-8, Dean 1-2, Keller 1-2, Newman 0-2, Thompson 0-4). Team Rebounds: 3. Team Turnovers: 1. Blocked Shots: 1 (Ousmane). Turnovers: 7 (Brantley 3, Dean, Jennings, Newman, Ousmane). Steals: 4 (Avery, Brantley, Dean, Newman). Technical Fouls: None. Percentages: FG .589, FT .680. 3-Point Goals: 7-18, .389 (Sanders 3-5, DuSell 2-4, Rolison 1-2, Davidson 1-4, T.Coleman 0-3). Team Rebounds: 1. Team Turnovers: 1. Blocked Shots: 3 (Love 2, Hymes). Turnovers: 9 (Rolison 2, Sanders 2, T.Coleman 2, Davidson, Hymes, McBride). Steals: 4 (Love 2, Davidson, Sanders). Technical Fouls: None. .
UNIVERSITY PARK — As No. 4 Penn State went through warmups at Beaver Stadium ahead of Saturday afternoon’s regular-season finale vs. Maryland, No. 2 Ohio State and Michigan were locked in a low-scoring duel with significant implications. A loss by the Buckeyes coupled with a Nittany Lions win would propel Penn State into the Big Ten championship game Dec. 7 vs. No. 1 Oregon. The Nittany Lions got the help they needed from Michigan, which upset Ohio State, and Penn State took things from there, overcoming a sluggish start to dispatch Maryland, 44-7, on senior day while punching a ticket to the league title game for the first time since 2016. Only 11 seconds into the game, Penn State (11-1, 8-1) was down 7-0, but the Nittany Lions scored 44 unanswered points. Drew Allar finished the day 17 of 26 for 171 yards and two total touchdowns, and Tyler Warren became the Big Ten’s single-season record holder for catches by a tight end (76) in addition to Penn State’s all-time leader in touchdowns by a tight end (17). Warren caught six passes for 68 yards and a touchdown, rushing three times for an additional 32 yards. Penn State amassed 412 yards of total offense and held Maryland to 194. Nick Singleton fumbled on Penn State’s first play of the game, with Maryland recovering at the 25-yard line before MJ Morris threw a touchdown pass to Kaden Prather on the Terrapins’ opening play. Penn State answered with a 49-yard field goal by Ryan Barker, making the score 7-3 with 12 minutes, 47 seconds left in the first quarter. Neither Penn State nor Maryland (4-8, 1-8) was productive for a large chunk of the opening quarter. However, the Nittany Lions eventually got their wheels turning, embarking on a 13-play, 60-yard touchdown drive, which Singleton capped with a short run from the 2-yard line to give his team a 10-7 lead with 12:53 left before halftime. Though Penn State’s offense didn’t shower itself in glory early, the defense came up with several big plays, including three first-quarter sacks and two picks in the first half. A few minutes after Singleton’s touchdown run, Penn State stuffed a Maryland fourth-and-1 try from the Terrapins’ 30-yard line. On Penn State’s ensuing drive, Allar scored on a keeper at the goal line, giving the Nittany Lions a 17-7 lead at the 10:11 mark. A wacky play on Penn State’s next possession set up a short Beau Pribula rushing touchdown, making the score 24-7. Faking a handoff to Singleton in the backfield, Allar lost the football, with Maryland’s defense swarming the backfield. But Allar shook off the pressure and, as he was being dragged down, managed to toss the football to Warren, who turned the broken play into a 29-yard gain, with Singleton adding another 18 on the ground to get the Nittany Lions to the goal line. Pribula did the rest as Penn State went up by 17 with 6:53 remaining in the first half. Audavion Collins intercepted Morris on the Terrapins’ next drive, leading to a 7-yard scoring pass to Warren and a 31-7 advantage. The Terrapins got themselves in good position to put some points on the board at the end of the half, but Tony Rojas intercepted Morris at Penn State’s 9-yard line. Maryland made a change at quarterback in the third quarter, inserting Champ Long, but it did not lead to improved offense. Following a scoreless third, Singleton put Penn State up 38-7 with an 18-yard touchdown run 46 seconds into the fourth. Singleton led the Nittany Lions backfield with 13 carries for 87 yards and two scores. Penn State pulled Allar from the game in the fourth quarter, and the Pribula-led offense penetrated as far as Maryland’s 12-yard line before being stopped on fourth down with 3:42 to play. With Morris back in the game late, Penn State picked him off for the third time. Dejuan Lane returned it 54 yards deep into Terrapins territory. Pribula hit Tyseer Denmark for a 15-yard score as time expired in the blowout.DENVER — Amid renewed interest in the killing of JonBenet Ramsey triggered in part by a new Netflix documentary, police in Boulder, Colorado, refuted assertions this week that there is viable evidence and leads about the 1996 killing of the 6-year-old girl that they are not pursuing. JonBenet Ramsey, who competed in beauty pageants, was found dead in the basement of her family's home in the college town of Boulder the day after Christmas in 1996. Her body was found several hours after her mother called 911 to say her daughter was missing and a ransom note was left behind. The gravesite of JonBenet Ramsey is covered with flowers Jan. 8, 1997, at St. James Episcopal Cemetery in Marietta, Ga. JonBenet was bludgeoned and strangled. Her death was ruled a homicide, but nobody was ever prosecuted. The details of the crime and video footage of JonBenet competing in pageants propelled the case into one of the highest-profile mysteries in the United States. The police comments came as part of their annual update on the investigation, a month before the 28th anniversary of JonBenet's killing. Police said they released it a little earlier due to the increased attention on the case, apparently referring to the three-part Netflix series "Cold Case: Who Killed JonBenet Ramsey." In a video statement, Boulder Police Chief Steve Redfearn said the department welcomes news coverage and documentaries about the killing of JonBenet, who would have been 34 this year, as a way to generate possible new leads. He said the department is committed to solving the case but needs to be careful about what it shares about the investigation to protect a possible future prosecution. "What I can tell you though, is we have thoroughly investigated multiple people as suspects throughout the years and we continue to be open-minded about what occurred as we investigate the tips that come in to detectives," he said. The Netflix documentary focuses on the mistakes made by police and the "media circus" surrounding the case. A police officer sits in her cruiser Jan. 3, 1997, outside the home in which 6-year-old JonBenet Ramsey was found murdered Dec. 26, 1996, in Boulder, Colo. Police were widely criticized for mishandling the early investigation into her death amid speculation that her family was responsible. However, a prosecutor cleared her parents, John and Patsy Ramsey, and brother Burke in 2008 based on new DNA evidence from JonBenet's clothing that pointed to the involvement of an "unexplained third party" in her slaying. The announcement by former district attorney Mary Lacy came two years after Patsy Ramsey died of cancer. Lacy called the Ramseys "victims of this crime." John Ramsey continued to speak out for the case to be solved. In 2022, he supported an online petition asking Colorado's governor to intervene in the investigation by putting an outside agency in charge of DNA testing in the case. In the Netflix documentary, he said he advocated for several items that were not prepared for DNA testing to be tested and for other items to be retested. He said the results should be put through a genealogy database. In recent years, investigators identified suspects in unsolved cases by comparing DNA profiles from crime scenes and to DNA testing results shared online by people researching their family trees. In 2021, police said in their annual update that DNA hadn't been ruled out to help solve the case, and in 2022 noted that some evidence could be "consumed" if DNA testing is done on it. Last year, police said they convened a panel of outside experts to review the investigation to give recommendations and determine if updated technologies or forensic testing might produce new leads. In the latest update, Redfearn said that review ended but police continue to work through and evaluate a "lengthy list of recommendations" from the panel. Receive the latest in local entertainment news in your inbox weekly!
As the leaves fall, the heat goes on, the temperatures drop and the sweaters and jackets are pulled from storage, it’s also a great time to think about making a pot of soup. Soup is one of the best comfort foods, perfect for those New England fall and winter days. Whether you fancy clam or corn chowder, a roasted butternut squash soup, a classic Italian sausage orzo or something unique like lasagna soup, there’s a special place in everyone’s heart for that big pot on the stove. We have found five recipes that are sure to make your mouth water. No matter what soup preference you may have, you’ll find something to cook for the whole family. This recipe is by . Ingredients Directions This recipe is by . Ingredients Directions This recipe is by . Ingredients Noodles: Soup Base: Cheese Mixture: Garnish: Directions This recipe is by . Ingredients Directions This recipe is by . Ingredients DirectionsThe AP Top 25 men’s college basketball poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . GREENVILLE, S.C. (AP) — Pjay Smith Jr. scored 23 points as Furman beat Princeton 69-63 on Saturday. Smith also added eight rebounds and four steals for the Paladins (9-1). Garrett Hien scored 10 points while going 5 of 10 and 0 of 4 from the free-throw line and added seven rebounds. Nick Anderson shot 3 for 9 from beyond the arc to finish with nine points. The Tigers (7-4) were led by Xaivian Lee, who posted 16 points, seven rebounds and five assists. Princeton also got 13 points and four assists from Dalen Davis. Caden Pierce also had 11 points and four steals. NEXT UP Up next for Furman is a Saturday matchup with South Carolina State at home, and Princeton hosts Monmouth on Tuesday. ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen
Former San Jose mayor celebrated at rotunda naming ceremonyThe College Football Playoff committee took SMU's wins over Alabama's strength of schedule, picking the Mustangs for the final at-large spot Sunday after a furious public debate and days of lobbying and arguing over which teams should make the 12-team field. SMU (11-2) showed it could compete against a traditional power, losing to Clemson 34-31 on a 56-yard field goal on the final play of the ACC championship game. The late-game rally probably did the trick. “I just think America saw SMU belongs," Mustangs coach Rhett Lashlee told ESPN on Sunday after his team got in. "We’re a team that has a chance to compete for this championship. And to some degree, I think we’re a little bit America’s team after last night.” The Mustangs, seeded 11th, will visit No. 6 seed Penn State in the first round. The bracket was expanded from four teams this season, but that didn’t help Alabama or save the committee from controversy that began over the past two weeks as the CFP rankings — and “data points” — were parsed and criticized. The squabbling wasn't limited to who should be in the field but also who should get consideration for first-round byes. The Crimson Tide (9-3) had quality wins against Georgia and South Carolina in their first season under coach Kalen DeBoer. Losses at Vanderbilt, Tennessee and Oklahoma proved costly. The 24-3 loss to Oklahoma was too much to overcome. The Sooners, who finished 6-6, rushed for 250 yards against the Crimson Tide and dominated despite having several key injuries. Alabama athletic director Greg Byrne said the committee's decision was not good for college football. “Disappointed with the outcome and felt we were one of the 12 best teams in the country,” Byrne said in a social media post. “We had an extremely challenging schedule and recognize there were two games in particular that we did not perform as well as we should have.” All of Alabama's losses came in conference play. Still, Byrne said he now will reconsider how his program schedules nonconference games. For now, the Crimson Tide will settle for playing Michigan in the ReliaQuest Bowl on Dec. 31. Several teams with strong seasons were left out besides the Crimson Tide, including Miami (two losses), South Carolina and Mississippi (three losses each). Committee chairman Warde Manuel explained that strength of schedule was valued — a comment that didn’t sit well with Ole Miss coach Lane Kiffin. “Is this fake news??? he didn’t actually really say that ....” Kiffin wrote on a social media post, tagging both the Alabama and SMU football accounts. SMU actually increased its strength of schedule from the previous season by switching from the American Athletic Conference to the ACC. The Mustangs’ only regular-season loss this year was a nonconference game at home to 10-win BYU in the third game of the season . The Mustangs won nine straight before the loss to Clemson. That didn't make the waiting easier on Sunday. SMU was the last qualifier announced. “Until we saw SMU up there, you know, you’re just hanging, hanging on the edge,” Lashlee said. There was more controversy. Big 12 Commissioner Brett Yormark said he didn't believe any Group of Five team should get the bye over a Power Four champion, citing strength of schedule. Mountain West Commissioner Gloria Nevarez pushed back hours ahead of the bracket announcement. “Participation in the College Football Playoff isn’t about entitlement,” she wrote on social media. “It should not be contingent upon a conference patch or the logo on the helmet. ... Boise State’s body of work this season, including an 11-game win streak, has earned it one of the top four seeds ahead of the Big 12 champion.” In the end, Boise State of the Mountain West got the No. 3 seed ahead of Big 12 champion Arizona State, which was seeded fourth. But both got first-round byes. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football
TIRUCHY: Gone are the days when the streets in the Railway Colony at Ponmalai would brim with love and joy as the members of the Anglo-Indian community would never miss the Christmas festivities but lately their celebrations have been confined to houses as the population has plummeted. “We are heartbroken,” says Hanzel Ross, a visibly shattered retired railway employee gazing at the empty streets. Hanzel’s frustration stems from an overwhelming decline in the number of Anglo-Indians from over 25,000 in Golden Rock and around 15,000 in other parts of Tiruchy to less than 500. Most of the Anglo-Indians were well-off in the past as most of them were employed in railways. The railways had built them quarters which, at present, are in a dilapidated condition. Gradually most of them left the place seeking a good fortune. “Once, music and songs would flow all along the streets but now, it looks pathetic and ghosty,” Hanzel said. Hanzel Ross’s grandfather had worked in the railways during the British period and his father worked post-independence. Hanzel noted how it was easy for them to secure a job in the railways as they had a good command of the English language. “We mingle with locals, but at the same time never compromise with our traditions. Many of us have Dutch or Portuguese roots, and our surnames have been passed down through generations. We were earlier referred to as Euro-Asians. ‘Anglo-Indian’ is a term of convenience,” says Lynda Peppin, a retired teacher. “We are all in touch though the younger generations started migrating abroad in the 1950s. But we ensure we never miss social gatherings, particularly the Christmas festivities. In those days, we used to gather in the Ponmalai Railway Institute. But now, as times changed, we book halls in the city and no one misses any gathering whether it is a birthday celebration or wedding event,” recalled Lynda. “Every family would have at least six children and the entire colony would be filled with children's laughter. During festival times, the place would turn into a carnival. We are a fun-loving community and weekends for us, mean get-togethers, dancing, singing, playing bingo, and fancy dress competitions,” Lynda said. Meanwhile, KC Neelamegam (59), a railway employee whose family lived in the railway colony for three generations said, “I lived in a street where the majority were Anglo-Indians. As children, even if we did small good things, they would appreciate and encourage us.” He further added during Christmas and New Year, the colony would be in a celebratory mood which is missing now. “I still remember them dancing on the wooden floor of the Railway Institute Hall throughout the night. The rhythmic sound from their dance steps is audible even till our houses,” recounts Neelamegam. Because there were many Anglo-Indian teachers in the Railways Mixed Higher Secondary School at Ponmalai, many children acquired the English language efficiently. “For instance, my youngest brother studied in that school. After finishing the catering course, he got a job in the USA and settled there mainly because he got well-versed in English with the help of those teachers,” said Neelamegam. However, gradually, many Anglo-Indians left the Railway Colony due to economic reasons as job opportunities dried up. Doulas Freeman, a retired employee of Golden Rock railway workshop, explains in the past, many Anglo-Indian girls pursued teacher training at Church Park Anglo-Indian Teacher Training School in Chennai and came to work as teachers in Tiruchy. “But now, even in private schools a degree in education is mandatory and so our people went abroad in search of employment as Anglo-Indians are most preferred,” he said, adding that many have obtained good jobs with better pay scales and settled in Australia, UK, USA, and Canada. Dilapidated railway quarters where Anglo-Indians lived in Tiruchy This was one main reason that rendered many households in Ponmalai quiet, pathetic, and ghostly because senior citizens are the only people living here now. Most of their children are abroad and they come to Ponmalai only during festivals, particularly Christmas. Ballroom at railway institute hall, a testimony of their joyful days The Railway Institute Hall in Tiruchy, built by the British in 1897, was considered the hub of Anglo-Indians’ social life in the city, especially towards the end of the year. The community comes together and makes merry during Christmas and New Year celebrations starting on December 23 and ending on January 2. According to senior members, the hall built in the colonial style with high ceilings was initially functioning as a staff recreation club. With arched doorways that open to passages on the side to accommodate large crowds, the stone-floored hall has hosted many social gatherings that involve music and dance. The hall is making a comeback as the railway authorities have been carrying out elaborate refurbishment works. A similar ballroom at Ponmalai railway colony once played a vital role in enhancing the social lives of Anglo-Indians. Music and dance were always part of their social gatherings. The ballroom had a wooden floor to accommodate dancing couples who would remain enticed in feet tapping sounds. However, the wooden floors have been replaced with stone floors now. “During the weekends and special occasions, the ballroom used to be filled with the community members whose celebrations span from dusk to dawn,” recalls J Benjamin (71), an auditor, whose family lived in the railway colony for three generations. The building has been renovated for other purposes. There is a library now and it has also become a meeting place for retired people now. Benjamin, a non-Anglo Indian, recalled that Anglo-Indians were very particular about their dress code, behaviour and attitudes. However, over time, the Anglo-Indian women started wearing sarees and have also started speaking in Tamil. The interracial marriages have rendered the community more ethnically diverse than before. Renovated 127-year-old ballroom near Tiruchy junction Speaking on how they were open to adapting different cultural practices, he said, “Many women started wearing saree, bindi, and mangalsutra. They even draw ‘kolams’, light kuthuvilakku (lamps) during celebrations, and even light small lamps for the Karthigai Deepam festival,” Benjamin said. Once experts in sports, now nowhere near railway ground The railway ground which is the centre of attraction in Ponmalai railway colony was once dominated by the Anglo-Indian community members as they excelled in the games like cricket, hockey, and football and even bagged several cups and trophies in national-level tournaments. “The non-Anglo-Indian people were just spectators,” recalls KC Neelamegam (59), a railway employee and environmentalist. Neelamegam, whose family has been residing in the railway colony for three generations, said that he would sit in the distance and watch how the Anglo-Indians played. “We used to admire their expertise and see how they move around. Every year, they bring laurels to Ponmalai and they used to tour across the country participating in tournaments,” he said. He pointed out that in a positive and healthy development, the youth from the Anglo-Indian community eventually started mingling with other youth and taught them sports. “Gradually the scenario changed and many non-Anglo-Indian youths ventured into the railway ground and various teams playing for Ponmalai railway colony,” he said. Railway ground in Ponmalai railway colony “In the past, the ground used to be filled with Anglo-Indian youth. But now only handpicked Anglo-Indians are in the sports as the population shrank due to migration abroad,” he explained.
'Implementation of BRI in mutual agreement'
What happens when 'The Simpsons' join 'Monday Night Football'? Find out during Bengals-CowboysPutin threatens UK with new ballistic missile as Ukraine war escalatesJonBenet Ramsey, who competed in beauty pageants, was found dead in the basement of her family's home in the college town of Boulder the day after Christmas in 1996. Her body was found several hours after her mother called 911 to say her daughter was missing and a ransom note was left behind. JonBenet was bludgeoned and strangled. Her death was ruled a homicide, but nobody was ever prosecuted. The details of the crime and video footage of JonBenet competing in pageants propelled the case into one of the highest-profile mysteries in the United States. The police comments came as part of their annual update on the investigation, a month before the 28th anniversary of JonBenet's killing. Police said they released it a little earlier due to the increased attention on the case, apparently referring to the three-part Netflix series "Cold Case: Who Killed JonBenet Ramsey." In a video statement, Boulder Police Chief Steve Redfearn said the department welcomes news coverage and documentaries about the killing of JonBenet, who would have been 34 this year, as a way to generate possible new leads. He said the department is committed to solving the case but needs to be careful about what it shares about the investigation to protect a possible future prosecution. "What I can tell you though, is we have thoroughly investigated multiple people as suspects throughout the years and we continue to be open-minded about what occurred as we investigate the tips that come in to detectives," he said. The Netflix documentary focuses on the mistakes made by police and the "media circus" surrounding the case. Police were widely criticized for mishandling the early investigation into her death amid speculation that her family was responsible. However, a prosecutor cleared her parents, John and Patsy Ramsey, and brother Burke in 2008 based on new DNA evidence from JonBenet's clothing that pointed to the involvement of an "unexplained third party" in her slaying. The announcement by former district attorney Mary Lacy came two years after Patsy Ramsey died of cancer. Lacy called the Ramseys "victims of this crime." John Ramsey continued to speak out for the case to be solved. In 2022, he supported an online petition asking Colorado's governor to intervene in the investigation by putting an outside agency in charge of DNA testing in the case. In the Netflix documentary, he said he advocated for several items that were not prepared for DNA testing to be tested and for other items to be retested. He said the results should be put through a genealogy database. In recent years, investigators identified suspects in unsolved cases by comparing DNA profiles from crime scenes and to DNA testing results shared online by people researching their family trees. In 2021, police said in their annual update that DNA hadn't been ruled out to help solve the case, and in 2022 noted that some evidence could be "consumed" if DNA testing is done on it. Last year, police said they convened a panel of outside experts to review the investigation to give recommendations and determine if updated technologies or forensic testing might produce new leads. In the latest update, Redfearn said that review ended but police continue to work through and evaluate a "lengthy list of recommendations" from the panel.
SCOTTSDALE, Ariz. (AP) — SMU had an anxious morning awaiting word from the College Football Playoff committee. The Mustangs believed they had a strong enough resume to get into the 12-team field, highlighted by two wins over ranked teams. Even so, a loss to Clemson in the Atlantic Coast Conference championship game was enough to spur trepidation; the committee could go with Alabama instead. The wait over, these ponies will ride on in one of the best seasons in school history. SMU earned the CFP's last at-large selection on Sunday and will open the College Football Playoff at Penn State on Dec. 21, with the winner moving on to face Boise State and electric running back Ashton Jeanty in the Dec. 31 Fiesta Bowl. The Mountain West champion Broncos (12-1) were awarded the No. 3 seed in the CFP over Big 12 champion Arizona State. “Brands like Alabama, brands like Clemson — the blue bloods of our sport — they’ve earned that right, but that doesn’t mean they should get the nod in situations like this,” SMU coach Rhett Lashlee said. "I was really proud and thankful that didn’t play into the final decision.” The Mustangs (11-2) had wins over No. 22 Louisville and No. 18 Pittsburgh, finishing their first ACC season 8-0 — best by a group of five team their first season after moving up to a power conference. It's SMU's best season since 1984, yet a 34-31 loss to No. 13 Clemson in the ACC title game Saturday night left doubt whether it would make the cut in the first year of the 12-team playoff. The committee went with SMU over Alabama, giving the Mustangs the No. 11 seed and the ACC two playoff teams a year after unbeaten Florida State was left out of the four-team bracket. “It hurt what happened to our league last year,” Lashlee said. ”It does kind of galvanize the conference a little bit.” Penn State has found stability under coach James Franklin since the Jerry Sandusky sexual abuse scandal led to the firing of longtime coach Joe Paterno in 2011. The Nittany Lions have won at least 10 games six times in 11 seasons under Franklin, punctuated by earning the CFP's No. 6 seed despite losing 45-37 to top-ranked Oregon in the Big Ten championship. Penn State got here with a defense that's top 10 in yards and points allowed per game, along with one of the nation's best tight ends in Tyler Warren, who has 88 catches for 1,062 yards and six touchdowns. “We're getting better, but we'll see — it's all going to be based how we do against SMU,” Franklin said. “It's all about what you do on a consistent basis.” SMU also had a long climb back to relevance. One of the nation's top programs in the 1980s, the Mustangs received the death penalty from the NCAA in 1987 for a pay-to-play scandal. SMU had a hard time gaining a footing in the years that followed, including a winless 2003 season, before earning four straight bowl berths under coach June Jones from 2009-12. Lashlee has ushered the Mustangs into a new era since taking over in 2022, leading them to three straight bowl games and consecutive 11-win seasons — the latest good enough for a CFP berth. “There’s obviously a lot of tradition and history at SMU,” Franklin said. “They’ve done a really good job.” Boise State has a strong history at the Fiesta Bowl, including a win over Oklahoma in 2007 in one of the most memorable bowl games ever. The Broncos finally broke through to the CFP in their first full season under coach Spencer Danielson, who retained the job after being named interim coach midway through last season. Boise State lost to Oregon by three early in the season, then closed the season with 11 straight wins behind Jeanty, who rushed for 2,497 yards this season — fourth-most in FBS history and 132 behind Barry Sanders' record. “Our guys deserved it, they earned it,” Danielson said. “Even in this, there's going to be people counting us out. ... That's awesome. That's what this place is built on, the blue-collar chip on the shoulder, counted out.” Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-footballShafay meets world trade developers delegation
Iceland votes for new a parliament after coalition dissolvedJosh Norris scores late power-play goal in the Senators' 3-1 victory over the Wild